Clinical Trial Update: The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis [Phase 2]

View source ↗

Summary

Phase 2b study results for NEOD001 in previously treated AL amyloidosis completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis

Drugs mentioned

• NEOD001 (NEOD001)

Snippet

Sponsor: Prothena Biosciences Ltd. | Conditions: AL Amyloidosis | Phase 2 | Status: COMPLETED | Results posted: 2019-04-05